Max Rady College of Medicine
Biochemistry and Medical Genetics
Room 309C – Basic Medical Sciences Building
745 Bannatyne Avenue
University of Manitoba
Winnipeg, Manitoba R3E 0J9
Genomics research has dramatically improved our understanding of human disease. Unfortunately, effective treatments are still lacking for many diseases and existing therapeutic interventions are often limited by severe adverse drug reactions.
The Drögemöller Lab uses large-scale genomic and computational analyses to improve our understanding of how genetic variation contributes to human disease and the treatment thereof. These data will guide the development of individualized treatments for rare and common disease.
This research is focused specifically on vulnerable and understudied populations (e.g. pediatric and maternal populations) as therapeutic agents are often not designed and tested with these patients in mind.
Dr. Drögemöller joined the University of Manitoba as an assistant professor in 2020 and is Canada Research Chair in Pharmacogenomics and Precision Medicine.
She received her PhD from Stellenbosch University in South Africa in 2013. She continued her training in pharmacogenomics and precision medicine at the University of British Columbia, where she completed a postdoctoral fellowship at the Canadian Pharmacogenomics Network for Drug Safety.
Her research has uncovered genetic variants that place individuals at increased risk for experiencing severe adverse drug reactions to therapeutic treatments. Building on this research, she has also been involved in the identification of variants that cause rare and potentially treatable inborn errors of metabolism.
Visit Britt Drögemöller's ORCID profile for a complete listing, or find her on Google Scholar.